Genmab A/S (LON: 0MGB)

Market Cap	10.87B
Revenue (ttm)	2.21B
Net Income (ttm)	524.69M
Shares Out	n/a
EPS (ttm)	8.06
PE Ratio	20.72
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,687
Average Volume	36,761
Open	1,558.75
Previous Close	1,525.72
Day's Range	1,510.00 - 1,581.00
52-Week Range	154.65 - 246.44
Beta	0.86
RSI	52.27
Earnings Date	Feb 14, 2025

About Genmab

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 2,204
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0MGB

Financial Performance

In 2023, Genmab's revenue was 16.47 billion, an increase of 13.57% compared to the previous year's 14.51 billion. Earnings were 4.35 billion, a decrease of -20.18%.

Financial numbers in DKK